Pharmacological ascorbate (AscH−) induces cytotoxicity and oxidative stress selectively in pancreatic cancer cells compared with normal cells. Positron emission tomography (PET) with the thymidine analog 3′-deoxy-3′-(18F) fluorothymidine (FLT) enables noninvasive imaging and quantification of the proliferation fraction of tumors. We hypothesized that the rate of tumor proliferation determined by FLT-PET imaging, would be inversely proportional to tumor susceptibility to pharmacological AscH−-based treatments. Indeed, there was decreased FLT uptake in human pancreatic cancer cells treated with AscH− in vitro, and this effect was abrogated by co-treatment with catalase. In separate experiments, cells were treated with AscH−, ionizing radiation or a combination of both. These studies demonstrated that combined AscH− and radiation treatment resulted in a significant decrease in FLT uptake that directly correlated with decreased clonogenic survival. MicroPET 18F-FLT scans of mice with pre-established tumors demonstrated that AscH− treatment induced radiosensitization compared to radiation treatment alone. These data support testing of pharmacological ascorbate as a radiosensitizer in pancreatic cancer as well as the use of FLT-PET to monitor response to therapy.
Fluorine-18-Labeled Thymidine Positron Emission Tomography (FLT-PET) as an Index of Cell Proliferation after Pharmacological Ascorbate-Based Therapy
- Views Icon Views
- Share Icon Share
- Search Site
John A. Cieslak, Zita A. Sibenaller, Susan A. Walsh, Laura L. Boles Ponto, Juan Du, John J. Sunderland, Joseph J. Cullen; Fluorine-18-Labeled Thymidine Positron Emission Tomography (FLT-PET) as an Index of Cell Proliferation after Pharmacological Ascorbate-Based Therapy. Radiat Res 1 January 2016; 185 (1): 31–38. doi: https://doi.org/10.1667/RR14203.1
Download citation file: